The shadow of generic challenges has repeatedly loomed around copyright’s famous drug, PDE5 Inhibitor, sparking questions about the future of connected drug portfolios. While first periods saw impressive profits, the patent lapse has opened the path for cheaper substitutes, likely lowering online pharmacy profitability and posing a real hazard fo